About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

UNKNOWNPhase 2

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

Prospektiv Randomisierte Multizentrische Phase II-Studie Zur Metastasenresektion Von Lungenfiliae (Poor-prognosis) Beim Klarzelligen Nierenzellkarzinom +/- Adjuvante Sunitinibtherapie über 1 Jahr SMAT - AN 20/04 Der AUO

NCT01216371•Association of Urologic Oncology (AUO)

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Renal Cell CarcinomaPulmonary Metastases

Interventions

Sunitinib

Placebo

Locations

11

Germany

Locations (11)

Universitätsmedizin Charité Berlin

Berlin, Germany

Franziskus Krankenhaus

Berlin, Germany

Helios Klinikum Emil von Behring

Berlin, Germany

university hospital of Düsseldorf

Düsseldorf, Germany

university hospital of Essen

Essen, Germany

Ruhrlandklinik Department of Thoracic Surgery

Essen, Germany

Key Dates

Start Date

October 1, 2010

Primary Completion Date

October 1, 2015

Completion Date

October 1, 2015

Last Updated

February 13, 2012

Related Studies

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

NCT07485114

Renal Cell Carcinoma (Kidney Cancer)Non Small Cell Lung Cancer+2 more

Ketogenic Dietary Intervention to Improve Response to Immunotherapy in Patients With Metastatic Melanoma and Metastatic Kidney Cancer

NCT06391099

Clinical Stage IV Cutaneous Melanoma AJCC v8Metastatic Cutaneous Melanoma+2 more

RECRUITINGPhase 3

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

NCT05738694

Renal Cell CarcinomaNeoadjuvant

RECRUITINGPhase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

NCT07227402

Renal Cell Carcinoma

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

NCT06349642

Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial Carcinoma+25 more

RECRUITINGPhase 1

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241

Clear Cell Renal Cell CarcinomaRenal Cell Carcinoma+7 more

View all related studies

Contacts

Susanne Krege, Priv. Doz. Dr. med.

CONTACT

02 151 / 334-23 81

Sponsors

Lead Sponsor

Association of Urologic Oncology (AUO)

Collaborators

University Hospital, Essen

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 13, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions